Idorsia plans to launch the hypertension therapy Tryvio in the US in H2 2024. Image Credit: JHVEPhoto / Shutterstock.

Switzerland-based Idorsia has received approval from the US Food and Drug Administration (FDA) for the use of Tryvio (aprocitentan) as a combination treatment for hypertension in patients whose blood pressure is inadequately controlled with other antihypertensive drugs.

The news comes a few months after the company signed a deal with Johnson & Johnson to reacquire global rights for Tryvio. Idorsia agreed to pay up to Sfr306m ($343.5m) contingent on the EU and US approvals of the drug.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Tryvio is an endothelin receptor antagonist, which inhibits the binding of endothelin, a vasoconstrictive peptide, to its receptors on smooth muscle cells which results in vasodilation, ultimately, leading to a reduction in blood pressure. Idorsia plans to launch Tryvio in the US in H2 2024.

The approval was based on the Phase II and Phase III trial data. Tryvio showed a reduction in blood pressure for up to 48 weeks in the Phase III PRECISION trial (NCT03541174). One of the main side effects of the drug was fluid retention, which can cause rapid weight gain and stiffness of joints.

The global market for resistant hypertension is expected to be worth $895m by 2030, according to a GlobalData market analysis. The main competitor for Tryvio for this indication is expected to be AstraZeneca’s baxdrostat. While Tryvio will have the first-to-market advantage, baxdrostat is expected to generate $506m in sales in 2030, compared to $141m estimated for Tryvio during the same period.

GlobalData is the parent company of Pharmaceutical Technology.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

AstraZeneca added baxdrostat to its portfolio as part of the $1.8bn acquisition of CinCor Pharma in January 2023. Baxdrostat is a selective aldosterone synthase inhibitor. The drug is being evaluated in a Phase III BaxHTN trial (NCT06034743). The study is expected to enrol up to 720 participants with resistant hypertension taking two or more hypertensives to control their blood pressure.

Another drug in development for treating resistant hypertension is Novartis’ XXB750, a natriuretic peptide receptor 1 (NPR1) agonist. The drug is being evaluated in a Phase II trial (NCT06034743). The study is expected to enrol up to 170 participants and will be completed in September 2024.